Anixa Biosciences, Inc. (ANIX) 10-Year Financial Performance & Capital Metrics

ANIX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Show more

Revenue $0
EBITDA -$12M +15.2%
Net Income -$11M +13.0%
EPS (Diluted) -0.34 +12.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -66.55% -12.0%
ROIC -57.06% -11.3%
Debt/Equity 0.01 +19.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM11.07%

EPS CAGR

10Y-

5Y-

3Y-

TTM111.69%

ROCE

10Y Avg-103.98%

5Y Avg-56.49%

3Y Avg-59.3%

Latest-70.48%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Sales/Revenue+	300K	362.5K	1.11M	250K	0	512K	0	210K	0	0
Revenue Growth %	-0.97%	0.21%	2.07%	-0.78%	-1%	-	-1%	-	-1%	-
Cost of Goods Sold+	217.42K	104.56K	1.09M	166.25K	90.16K	385K	0	161K	0	0
COGS % of Revenue	0.72%	0.29%	0.98%	0.67%	-	0.75%	-	0.77%	-	-
Gross Profit+	82.58K	257.94K	18.79K	83.75K	-90.16K	127K	0	49K	0	0
Gross Margin %	0.28%	0.71%	0.02%	0.34%	-	0.25%	-	0.23%	-	-
Gross Profit Growth %	-0.99%	2.12%	-0.93%	3.46%	-2.08%	2.41%	-1%	-	-1%	-
Operating Expenses+	4.59M	6.33M	13.72M	11.97M	9.89M	13.26M	13.88M	11.06M	13.83M	11.7M
OpEx % of Revenue	15.31%	17.47%	12.34%	47.9%	-	25.9%	-	52.67%	-	-
Selling, General & Admin	2.71M	4.41M	6.91M	5.66M	5.51M	7.07M	7.17M	6.29M	7.43M	6.63M
SG&A % of Revenue	9.03%	12.17%	6.21%	22.65%	-	13.82%	-	29.96%	-	-
Research & Development	1.56M	1.6M	6.81M	5.47M	4.38M	6.19M	6.7M	4.77M	6.4M	5.07M
R&D % of Revenue	5.19%	4.41%	6.12%	21.89%	-	12.09%	-	22.71%	-	-
Other Operating Expenses	0	-13.1K	0	837.5K	0	0	0	0	0	0
Operating Income+	-4.51M	-6.08M	-13.71M	-11.89M	-9.98M	-13.14M	-13.88M	-11.01M	-13.83M	-11.7M
Operating Margin %	-15.03%	-16.76%	-12.32%	-47.56%	-	-25.66%	-	-52.43%	-	-
Operating Income Growth %	-3.77%	-0.35%	-1.26%	0.13%	0.16%	-0.32%	-0.06%	0.21%	-0.26%	0.15%
EBITDA+	-4.15M	-5.71M	-13.36M	-11.42M	-9.89M	-13.08M	-13.83M	-10.96M	-13.79M	-11.7M
EBITDA Margin %	-13.83%	-15.74%	-12.01%	-45.69%	-	-25.54%	-	-52.21%	-	-
EBITDA Growth %	-5.84%	-0.38%	-1.34%	0.15%	0.13%	-0.32%	-0.06%	0.21%	-0.26%	0.15%
D&A (Non-Cash Add-back)	358.63K	368.51K	343.73K	466.31K	90.16K	59.86K	42K	46K	37K	0
EBIT	-4.5M	-4.51M	-14.24M	-11.47M	-10.09M	-13.14M	-13.77M	-11.01M	-12.7M	0
Net Interest Income+	-507.42K	-481.01K	45.97K	71.35K	33.92K	2K	0	1.08M	1.13M	0
Interest Income	12.53K	19.44K	45.97K	71.35K	33.92K	2.32K	104K	1.08M	1.13M	673K
Interest Expense	519.95K	500.45K	0	0	0	322	104K	0	0	0
Other Income/Expense	-507.42K	1.07M	-537K	71.35K	-114.16K	7.77K	104K	1.08M	1.13M	774K
Pretax Income+	-5.02M	-5.01M	-14.24M	-11.82M	-10.09M	-13.13M	-13.77M	-9.93M	-12.7M	-10.93M
Pretax Margin %	-16.72%	-13.82%	-12.8%	-47.27%	-	-25.64%	-	-47.29%	-	-
Income Tax+	12.53K	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.98%	0.99%	1%	0.99%	0.99%	0.99%	0.99%	1%
Net Income+	-5.02M	-5.01M	-14M	-11.65M	-10.13M	-12.95M	-13.6M	-9.81M	-12.55M	-10.93M
Net Margin %	-16.72%	-13.82%	-12.58%	-46.59%	-	-25.29%	-	-46.72%	-	-
Net Income Growth %	-2.64%	0%	-1.79%	0.17%	0.13%	-0.28%	-0.05%	0.28%	-0.28%	0.13%
Net Income (Continuing)	-5.02M	-5.01M	-14.24M	-11.82M	-10.09M	-13.13M	-13.77M	-9.93M	-12.7M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	-251.38K	-422.98K	-496.98K	-670.51K	-847K	-966K	-1.11M	-1.21M
EPS (Diluted)+	-0.57	-0.41	-0.79	-0.61	-0.46	-0.45	-0.45	-0.32	-0.39	-0.34
EPS Growth %	-3.07%	0.28%	-0.93%	0.23%	0.25%	0.02%	0%	0.29%	-0.22%	0.13%
EPS (Basic)	-0.57	-0.41	-0.79	-0.61	-0.46	-0.45	-0.45	-0.32	-0.39	-0.34
Diluted Shares Outstanding	8.74M	12.2M	17.62M	19.79M	22.23M	28.58M	30.37M	30.98M	31.9M	32.45M
Basic Shares Outstanding	8.74M	12.2M	17.62M	19.79M	22.23M	28.58M	30.37M	30.98M	31.9M	32.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Total Current Assets+	3.4M	7.01M	5.54M	6.09M	9.37M	36M	30.2M	25.36M	21.36M	15.89M
Cash & Short-Term Investments	3.24M	6.84M	5.06M	5.84M	9.06M	35.73M	29.69M	23.84M	19.92M	1.24M
Cash Only	2.49M	3.34M	3.06M	3.49M	6.42M	29.13M	12.36M	915K	1.27M	1.24M
Short-Term Investments	750K	3.5M	2M	2.35M	2.64M	6.6M	17.33M	22.93M	18.65M	0
Accounts Receivable	0	0	306.99K	66.53K	2.23K	0	46K	270K	173K	0
Days Sales Outstanding	-	-	100.72	97.13	-	-	-	469.29	-	-
Inventory	0	0	0	-2.35M	0	0	-46K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	-2.23K	-444	46K	1.24M	1.26M	14.64M
Total Non-Current Assets+	2.23M	1.8M	910.17K	200.57K	84.34K	253.96K	212K	166K	229K	193K
Property, Plant & Equipment	156.64K	52.7K	72.67K	200.57K	54.34K	253.96K	212K	166K	229K	193K
Fixed Asset Turnover	1.92x	6.88x	15.31x	1.25x	-	2.02x	-	1.27x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	2.07M	1.75M	837.5K	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	30K	0	0	0	0	0
Total Assets+	5.63M	8.81M	6.45M	6.29M	9.45M	36.26M	30.41M	25.52M	21.59M	16.08M
Asset Turnover	0.05x	0.04x	0.17x	0.04x	-	0.01x	-	0.01x	-	-
Asset Growth %	-0.4%	0.57%	-0.27%	-0.02%	0.5%	2.84%	-0.16%	-0.16%	-0.15%	-0.26%
Total Current Liabilities+	468.76K	889.49K	1.27M	1.48M	1.19M	1.27M	2.04M	2.03M	2.5M	1.97M
Accounts Payable	373.22K	480.32K	582.01K	585.82K	232.37K	136K	265K	206K	525K	165K
Days Payables Outstanding	626.57	1.68K	194.23	1.29K	940.74	128.94	-	467.02	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	41K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	1.93M
Current Ratio	7.25x	7.89x	4.38x	4.11x	7.88x	28.35x	14.83x	12.50x	8.54x	8.08x
Quick Ratio	7.25x	7.89x	4.38x	5.70x	7.88x	28.35x	14.85x	12.50x	8.54x	8.08x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.17M	480.32K	582.01K	0	0	220.08K	175K	123K	203K	163K
Long-Term Debt	0	0	0	0	0	0	0	0	0	163K
Capital Lease Obligations	0	0	0	0	0	220K	175K	123K	203K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	4.17M	0	0	0	0	82	0	0	0	0
Total Liabilities	4.64M	889.49K	1.27M	1.48M	1.19M	1.49M	2.21M	2.15M	2.7M	2.13M
Total Debt+	4.17M	0	0	0	55.2K	259K	221K	175K	232K	204K
Net Debt	1.68M	-3.34M	-3.06M	-3.49M	-6.36M	-28.83M	-12.14M	-740K	-1.04M	-1.04M
Debt / Equity	4.22x	-	-	-	0.01x	0.01x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-8.67x	-12.14x	-	-	-	-40794.07x	-133.41x	-	-	-
Total Equity+	987.48K	7.92M	5.18M	4.81M	8.26M	34.77M	28.2M	23.37M	18.89M	13.95M
Equity Growth %	-0.8%	7.02%	-0.35%	-0.07%	0.72%	3.21%	-0.19%	-0.17%	-0.19%	-0.26%
Book Value per Share	0.11	0.65	0.29	0.24	0.37	1.22	0.93	0.75	0.59	0.43
Total Shareholders' Equity	987.48K	7.92M	5.43M	5.24M	8.76M	35.44M	29.05M	24.34M	20M	15.16M
Common Stock	87.52K	166.03K	189.09K	203.32K	242.49K	300.51K	309K	311K	322K	330K
Retained Earnings	-151.17M	-156.17M	-170.17M	-181.82M	-191.84M	-204.79M	-218.38M	-228.2M	-240.75M	-251.68M
Treasury Stock	0	0	0	0	0	0	0	0	-6K	0
Accumulated OCI	-101.52K	-35.73K	0	0	0	0	0	0	0	0
Minority Interest	0	0	-251.38K	-422.98K	-496.98K	-670.51K	-847K	-966K	-1.11M	-1.21M

Cash Flow

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Cash from Operations+	-3.38M	-3.8M	-4.27M	-4.74M	-6.18M	-4.94M	-6.49M	-6.21M	-7.33M	-7.17M
Operating CF Margin %	-11.27%	-10.47%	-3.84%	-18.97%	-	-9.64%	-	-29.57%	-	-
Operating CF Growth %	-3.48%	-0.12%	-0.13%	-0.11%	-0.3%	0.2%	-0.32%	0.04%	-0.18%	0.02%
Net Income	-5.02M	-5.01M	-14.24M	-11.82M	-10.09M	-13.13M	-13.77M	-9.93M	-12.7M	-11.03M
Depreciation & Amortization	358.63K	368.51K	343.73K	466.31K	90.16K	59.86K	42K	46K	37K	-107K
Stock-Based Compensation	873.56K	1.22M	8.9M	5.71M	3.92M	8.06M	6M	4.42M	4.42M	3.68M
Deferred Taxes	0	45.91K	647.63K	0	0	0	0	0	0	0
Other Non-Cash Items	563.11K	-833.16K	15K	418.75K	362.82K	-5.37K	752K	313K	380K	281K
Working Capital Changes	-160.57K	408.24K	67.7K	478.42K	-459.01K	78.55K	485K	-1.06M	526K	0
Change in Receivables	0	107.1K	-258.99K	271.7K	64.3K	0	-29K	-224K	97K	173K
Change in Inventory	0	0	0	-271.7K	-64.3K	0	29K	224K	0	0
Change in Payables	87.99K	107.1K	101.69K	3.81K	-353.45K	-96.17K	129K	-59K	319K	-360K
Cash from Investing+	1.5M	-2.74M	1.46M	-525.46K	-305.79K	-3.92M	-10.73M	-5.6M	4.28M	4.87M
Capital Expenditures	-146.52K	-30.19K	-38.4K	-175.46K	-15.79K	0	0	0	0	0
CapEx % of Revenue	0.49%	0.08%	0.03%	0.7%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.9M	45K	-4.25M	-3.85M	-5.01M	35.45K	0	0	0	-44.36M
Cash from Financing+	-2.68K	7.38M	2.53M	5.7M	9.41M	31.57M	452K	366K	3.42M	2.28M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.68K	7.38M	58.14K	175.19K	140.72K	439.79K	0	0	466K	2.28M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.53M	-3.83M	-4.31M	-4.92M	-6.19M	-4.94M	-6.49M	-6.21M	-7.33M	-7.17M
FCF Margin %	-11.76%	-10.56%	-3.88%	-19.67%	-	-9.64%	-	-29.57%	-	-
FCF Growth %	-3.7%	-0.08%	-0.13%	-0.14%	-0.26%	0.2%	-0.32%	0.04%	-0.18%	0.02%
FCF per Share	-0.40	-0.31	-0.24	-0.25	-0.28	-0.17	-0.21	-0.20	-0.23	-0.22
FCF Conversion (FCF/Net Income)	0.67x	0.76x	0.31x	0.41x	0.61x	0.38x	0.48x	0.63x	0.58x	0.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-166.08%	-112.43%	-213.58%	-233.04%	-154.97%	-60.17%	-43.18%	-38.05%	-59.41%	-66.55%
Return on Invested Capital (ROIC)	-201.57%	-125.62%	-306.35%	-517.21%	-464.35%	-252.61%	-94.78%	-42.69%	-51.25%	-57.06%
Gross Margin	27.53%	71.16%	1.69%	33.5%	-	24.8%	-	23.33%	-	-
Net Margin	-1672.14%	-1381.79%	-1258.07%	-4658.82%	-	-2528.64%	-	-4671.9%	-	-
Debt / Equity	4.22x	-	-	-	0.01x	0.01x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-8.67x	-12.14x	-	-	-	-40794.07x	-133.41x	-	-	-
FCF Conversion	0.67x	0.76x	0.31x	0.41x	0.61x	0.38x	0.48x	0.63x	0.58x	0.66x
Revenue Growth	-96.76%	20.83%	206.9%	-77.53%	-100%	-	-100%	-	-100%	-

Revenue by Segment

	2012	2019
Patent Licensing	-	250K
Patent Licensing Growth	-	-

Revenue by Geography

	2012	2019
Taiwan	940.01K	-
Taiwan Growth	-	-
United States	4.28K	-
United States Growth	-	-

Frequently Asked Questions

Growth & Financials

Anixa Biosciences, Inc. (ANIX) grew revenue by 0.0% over the past year. Growth has been modest.

Anixa Biosciences, Inc. (ANIX) reported a net loss of $11.1M for fiscal year 2025.

Dividend & Returns

Anixa Biosciences, Inc. (ANIX) has a return on equity (ROE) of -66.6%. Negative ROE indicates the company is unprofitable.

Anixa Biosciences, Inc. (ANIX) had negative free cash flow of $6.8M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Anixa Biosciences, Inc. (ANIX) 10-Year Financial Performance & Capital Metrics

ANIX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$12M +15.2%
Net Income -$11M +13.0%
EPS (Diluted) -0.34 +12.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -66.55% -12.0%
ROIC -57.06% -11.3%
Debt/Equity 0.01 +19.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM11.07%

EPS CAGR

10Y-

5Y-

3Y-

TTM111.69%

ROCE

10Y Avg-103.98%

5Y Avg-56.49%

3Y Avg-59.3%

Latest-70.48%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Sales/Revenue+	300K	362.5K	1.11M	250K	0	512K	0	210K	0	0
Revenue Growth %	-0.97%	0.21%	2.07%	-0.78%	-1%	-	-1%	-	-1%	-
Cost of Goods Sold+	217.42K	104.56K	1.09M	166.25K	90.16K	385K	0	161K	0	0
COGS % of Revenue	0.72%	0.29%	0.98%	0.67%	-	0.75%	-	0.77%	-	-
Gross Profit+	82.58K	257.94K	18.79K	83.75K	-90.16K	127K	0	49K	0	0
Gross Margin %	0.28%	0.71%	0.02%	0.34%	-	0.25%	-	0.23%	-	-
Gross Profit Growth %	-0.99%	2.12%	-0.93%	3.46%	-2.08%	2.41%	-1%	-	-1%	-
Operating Expenses+	4.59M	6.33M	13.72M	11.97M	9.89M	13.26M	13.88M	11.06M	13.83M	11.7M
OpEx % of Revenue	15.31%	17.47%	12.34%	47.9%	-	25.9%	-	52.67%	-	-
Selling, General & Admin	2.71M	4.41M	6.91M	5.66M	5.51M	7.07M	7.17M	6.29M	7.43M	6.63M
SG&A % of Revenue	9.03%	12.17%	6.21%	22.65%	-	13.82%	-	29.96%	-	-
Research & Development	1.56M	1.6M	6.81M	5.47M	4.38M	6.19M	6.7M	4.77M	6.4M	5.07M
R&D % of Revenue	5.19%	4.41%	6.12%	21.89%	-	12.09%	-	22.71%	-	-
Other Operating Expenses	0	-13.1K	0	837.5K	0	0	0	0	0	0
Operating Income+	-4.51M	-6.08M	-13.71M	-11.89M	-9.98M	-13.14M	-13.88M	-11.01M	-13.83M	-11.7M
Operating Margin %	-15.03%	-16.76%	-12.32%	-47.56%	-	-25.66%	-	-52.43%	-	-
Operating Income Growth %	-3.77%	-0.35%	-1.26%	0.13%	0.16%	-0.32%	-0.06%	0.21%	-0.26%	0.15%
EBITDA+	-4.15M	-5.71M	-13.36M	-11.42M	-9.89M	-13.08M	-13.83M	-10.96M	-13.79M	-11.7M
EBITDA Margin %	-13.83%	-15.74%	-12.01%	-45.69%	-	-25.54%	-	-52.21%	-	-
EBITDA Growth %	-5.84%	-0.38%	-1.34%	0.15%	0.13%	-0.32%	-0.06%	0.21%	-0.26%	0.15%
D&A (Non-Cash Add-back)	358.63K	368.51K	343.73K	466.31K	90.16K	59.86K	42K	46K	37K	0
EBIT	-4.5M	-4.51M	-14.24M	-11.47M	-10.09M	-13.14M	-13.77M	-11.01M	-12.7M	0
Net Interest Income+	-507.42K	-481.01K	45.97K	71.35K	33.92K	2K	0	1.08M	1.13M	0
Interest Income	12.53K	19.44K	45.97K	71.35K	33.92K	2.32K	104K	1.08M	1.13M	673K
Interest Expense	519.95K	500.45K	0	0	0	322	104K	0	0	0
Other Income/Expense	-507.42K	1.07M	-537K	71.35K	-114.16K	7.77K	104K	1.08M	1.13M	774K
Pretax Income+	-5.02M	-5.01M	-14.24M	-11.82M	-10.09M	-13.13M	-13.77M	-9.93M	-12.7M	-10.93M
Pretax Margin %	-16.72%	-13.82%	-12.8%	-47.27%	-	-25.64%	-	-47.29%	-	-
Income Tax+	12.53K	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.98%	0.99%	1%	0.99%	0.99%	0.99%	0.99%	1%
Net Income+	-5.02M	-5.01M	-14M	-11.65M	-10.13M	-12.95M	-13.6M	-9.81M	-12.55M	-10.93M
Net Margin %	-16.72%	-13.82%	-12.58%	-46.59%	-	-25.29%	-	-46.72%	-	-
Net Income Growth %	-2.64%	0%	-1.79%	0.17%	0.13%	-0.28%	-0.05%	0.28%	-0.28%	0.13%
Net Income (Continuing)	-5.02M	-5.01M	-14.24M	-11.82M	-10.09M	-13.13M	-13.77M	-9.93M	-12.7M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	-251.38K	-422.98K	-496.98K	-670.51K	-847K	-966K	-1.11M	-1.21M
EPS (Diluted)+	-0.57	-0.41	-0.79	-0.61	-0.46	-0.45	-0.45	-0.32	-0.39	-0.34
EPS Growth %	-3.07%	0.28%	-0.93%	0.23%	0.25%	0.02%	0%	0.29%	-0.22%	0.13%
EPS (Basic)	-0.57	-0.41	-0.79	-0.61	-0.46	-0.45	-0.45	-0.32	-0.39	-0.34
Diluted Shares Outstanding	8.74M	12.2M	17.62M	19.79M	22.23M	28.58M	30.37M	30.98M	31.9M	32.45M
Basic Shares Outstanding	8.74M	12.2M	17.62M	19.79M	22.23M	28.58M	30.37M	30.98M	31.9M	32.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Total Current Assets+	3.4M	7.01M	5.54M	6.09M	9.37M	36M	30.2M	25.36M	21.36M	15.89M
Cash & Short-Term Investments	3.24M	6.84M	5.06M	5.84M	9.06M	35.73M	29.69M	23.84M	19.92M	1.24M
Cash Only	2.49M	3.34M	3.06M	3.49M	6.42M	29.13M	12.36M	915K	1.27M	1.24M
Short-Term Investments	750K	3.5M	2M	2.35M	2.64M	6.6M	17.33M	22.93M	18.65M	0
Accounts Receivable	0	0	306.99K	66.53K	2.23K	0	46K	270K	173K	0
Days Sales Outstanding	-	-	100.72	97.13	-	-	-	469.29	-	-
Inventory	0	0	0	-2.35M	0	0	-46K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	-2.23K	-444	46K	1.24M	1.26M	14.64M
Total Non-Current Assets+	2.23M	1.8M	910.17K	200.57K	84.34K	253.96K	212K	166K	229K	193K
Property, Plant & Equipment	156.64K	52.7K	72.67K	200.57K	54.34K	253.96K	212K	166K	229K	193K
Fixed Asset Turnover	1.92x	6.88x	15.31x	1.25x	-	2.02x	-	1.27x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	2.07M	1.75M	837.5K	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	30K	0	0	0	0	0
Total Assets+	5.63M	8.81M	6.45M	6.29M	9.45M	36.26M	30.41M	25.52M	21.59M	16.08M
Asset Turnover	0.05x	0.04x	0.17x	0.04x	-	0.01x	-	0.01x	-	-
Asset Growth %	-0.4%	0.57%	-0.27%	-0.02%	0.5%	2.84%	-0.16%	-0.16%	-0.15%	-0.26%
Total Current Liabilities+	468.76K	889.49K	1.27M	1.48M	1.19M	1.27M	2.04M	2.03M	2.5M	1.97M
Accounts Payable	373.22K	480.32K	582.01K	585.82K	232.37K	136K	265K	206K	525K	165K
Days Payables Outstanding	626.57	1.68K	194.23	1.29K	940.74	128.94	-	467.02	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	41K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	1.93M
Current Ratio	7.25x	7.89x	4.38x	4.11x	7.88x	28.35x	14.83x	12.50x	8.54x	8.08x
Quick Ratio	7.25x	7.89x	4.38x	5.70x	7.88x	28.35x	14.85x	12.50x	8.54x	8.08x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.17M	480.32K	582.01K	0	0	220.08K	175K	123K	203K	163K
Long-Term Debt	0	0	0	0	0	0	0	0	0	163K
Capital Lease Obligations	0	0	0	0	0	220K	175K	123K	203K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	4.17M	0	0	0	0	82	0	0	0	0
Total Liabilities	4.64M	889.49K	1.27M	1.48M	1.19M	1.49M	2.21M	2.15M	2.7M	2.13M
Total Debt+	4.17M	0	0	0	55.2K	259K	221K	175K	232K	204K
Net Debt	1.68M	-3.34M	-3.06M	-3.49M	-6.36M	-28.83M	-12.14M	-740K	-1.04M	-1.04M
Debt / Equity	4.22x	-	-	-	0.01x	0.01x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-8.67x	-12.14x	-	-	-	-40794.07x	-133.41x	-	-	-
Total Equity+	987.48K	7.92M	5.18M	4.81M	8.26M	34.77M	28.2M	23.37M	18.89M	13.95M
Equity Growth %	-0.8%	7.02%	-0.35%	-0.07%	0.72%	3.21%	-0.19%	-0.17%	-0.19%	-0.26%
Book Value per Share	0.11	0.65	0.29	0.24	0.37	1.22	0.93	0.75	0.59	0.43
Total Shareholders' Equity	987.48K	7.92M	5.43M	5.24M	8.76M	35.44M	29.05M	24.34M	20M	15.16M
Common Stock	87.52K	166.03K	189.09K	203.32K	242.49K	300.51K	309K	311K	322K	330K
Retained Earnings	-151.17M	-156.17M	-170.17M	-181.82M	-191.84M	-204.79M	-218.38M	-228.2M	-240.75M	-251.68M
Treasury Stock	0	0	0	0	0	0	0	0	-6K	0
Accumulated OCI	-101.52K	-35.73K	0	0	0	0	0	0	0	0
Minority Interest	0	0	-251.38K	-422.98K	-496.98K	-670.51K	-847K	-966K	-1.11M	-1.21M

Cash Flow

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Cash from Operations+	-3.38M	-3.8M	-4.27M	-4.74M	-6.18M	-4.94M	-6.49M	-6.21M	-7.33M	-7.17M
Operating CF Margin %	-11.27%	-10.47%	-3.84%	-18.97%	-	-9.64%	-	-29.57%	-	-
Operating CF Growth %	-3.48%	-0.12%	-0.13%	-0.11%	-0.3%	0.2%	-0.32%	0.04%	-0.18%	0.02%
Net Income	-5.02M	-5.01M	-14.24M	-11.82M	-10.09M	-13.13M	-13.77M	-9.93M	-12.7M	-11.03M
Depreciation & Amortization	358.63K	368.51K	343.73K	466.31K	90.16K	59.86K	42K	46K	37K	-107K
Stock-Based Compensation	873.56K	1.22M	8.9M	5.71M	3.92M	8.06M	6M	4.42M	4.42M	3.68M
Deferred Taxes	0	45.91K	647.63K	0	0	0	0	0	0	0
Other Non-Cash Items	563.11K	-833.16K	15K	418.75K	362.82K	-5.37K	752K	313K	380K	281K
Working Capital Changes	-160.57K	408.24K	67.7K	478.42K	-459.01K	78.55K	485K	-1.06M	526K	0
Change in Receivables	0	107.1K	-258.99K	271.7K	64.3K	0	-29K	-224K	97K	173K
Change in Inventory	0	0	0	-271.7K	-64.3K	0	29K	224K	0	0
Change in Payables	87.99K	107.1K	101.69K	3.81K	-353.45K	-96.17K	129K	-59K	319K	-360K
Cash from Investing+	1.5M	-2.74M	1.46M	-525.46K	-305.79K	-3.92M	-10.73M	-5.6M	4.28M	4.87M
Capital Expenditures	-146.52K	-30.19K	-38.4K	-175.46K	-15.79K	0	0	0	0	0
CapEx % of Revenue	0.49%	0.08%	0.03%	0.7%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.9M	45K	-4.25M	-3.85M	-5.01M	35.45K	0	0	0	-44.36M
Cash from Financing+	-2.68K	7.38M	2.53M	5.7M	9.41M	31.57M	452K	366K	3.42M	2.28M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.68K	7.38M	58.14K	175.19K	140.72K	439.79K	0	0	466K	2.28M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.53M	-3.83M	-4.31M	-4.92M	-6.19M	-4.94M	-6.49M	-6.21M	-7.33M	-7.17M
FCF Margin %	-11.76%	-10.56%	-3.88%	-19.67%	-	-9.64%	-	-29.57%	-	-
FCF Growth %	-3.7%	-0.08%	-0.13%	-0.14%	-0.26%	0.2%	-0.32%	0.04%	-0.18%	0.02%
FCF per Share	-0.40	-0.31	-0.24	-0.25	-0.28	-0.17	-0.21	-0.20	-0.23	-0.22
FCF Conversion (FCF/Net Income)	0.67x	0.76x	0.31x	0.41x	0.61x	0.38x	0.48x	0.63x	0.58x	0.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-166.08%	-112.43%	-213.58%	-233.04%	-154.97%	-60.17%	-43.18%	-38.05%	-59.41%	-66.55%
Return on Invested Capital (ROIC)	-201.57%	-125.62%	-306.35%	-517.21%	-464.35%	-252.61%	-94.78%	-42.69%	-51.25%	-57.06%
Gross Margin	27.53%	71.16%	1.69%	33.5%	-	24.8%	-	23.33%	-	-
Net Margin	-1672.14%	-1381.79%	-1258.07%	-4658.82%	-	-2528.64%	-	-4671.9%	-	-
Debt / Equity	4.22x	-	-	-	0.01x	0.01x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-8.67x	-12.14x	-	-	-	-40794.07x	-133.41x	-	-	-
FCF Conversion	0.67x	0.76x	0.31x	0.41x	0.61x	0.38x	0.48x	0.63x	0.58x	0.66x
Revenue Growth	-96.76%	20.83%	206.9%	-77.53%	-100%	-	-100%	-	-100%	-

Revenue by Segment

	2012	2019
Patent Licensing	-	250K
Patent Licensing Growth	-	-

Revenue by Geography

	2012	2019
Taiwan	940.01K	-
Taiwan Growth	-	-
United States	4.28K	-
United States Growth	-	-

Frequently Asked Questions

Growth & Financials

Anixa Biosciences, Inc. (ANIX) grew revenue by 0.0% over the past year. Growth has been modest.

Anixa Biosciences, Inc. (ANIX) reported a net loss of $11.1M for fiscal year 2025.

Dividend & Returns

Anixa Biosciences, Inc. (ANIX) has a return on equity (ROE) of -66.6%. Negative ROE indicates the company is unprofitable.

Anixa Biosciences, Inc. (ANIX) had negative free cash flow of $6.8M in fiscal year 2025, likely due to heavy capital investments.